Documents informatifs

Documents informatifs

Découvrez les documents informatifs de l’IMPACT Academy.

Veuillez saisir au moins 3 caractères
Featured
PLUS RÉCENT

Contenu recommandé

COVID-19 and its implications in heart failure
PRÉSENTATION
COVID-19 and its implications in heart failure
Afficher le contenu
Can new-onset diabetes be prevented
PRÉSENTATION
Can new-onset diabetes be prevented
Afficher le contenu
Practicalities of SGLT2 inhibition – pros vs cons
INFOGRAPHIC
Practicalities of SGLT2 inhibition – pros vs cons
Afficher le contenu
Updates on ESC heart failure guidelines
Vidéo
Updates on ESC heart failure guidelines
Afficher le contenu
Cardiologist Practical Guide to Prescribing
INFOGRAPHIC
Cardiologist Practical Guide to Prescribing
Afficher le contenu
Cardiovascular
PLUS RÉCENT

Cardiovasculaire

Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
Vidéo
Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
Afficher le contenu
What did the study tell us about the safety of medicines in heart failure?
INFOGRAPHIC
What did the study tell us about the safety of medicines in heart failure?
Afficher le contenu
Hiding in plain sight – how to detect heart failure in primary care
Vidéo
Hiding in plain sight – how to detect heart failure in primary care
Afficher le contenu
Optimizing HF discharge care and follow-up
INFOGRAPHIC
Optimizing HF discharge care and follow-up
Afficher le contenu
Afficher toutes les ressources Cardiovasculaire
Infection and Vaccines
PLUS RÉCENT

Infections et vaccins

Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
Vidéo
Mechanisms behind the cardiovascular benefits of SGLT2 inhibitors
Afficher le contenu
What did the study tell us about the safety of medicines in heart failure?
INFOGRAPHIC
What did the study tell us about the safety of medicines in heart failure?
Afficher le contenu
Optimizing HF discharge care and follow-up
INFOGRAPHIC
Optimizing HF discharge care and follow-up
Afficher le contenu
Renal protection with SGLT2 inhibitors: what every cardiologist should know
INFOGRAPHIC
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Afficher le contenu
Afficher toutes les ressources Infections et vaccins
Metabolic
PLUS RÉCENT

Métabolique

Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
Vidéo
Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
Afficher le contenu
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
INFOGRAPHIC
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Afficher le contenu
Clinical recommendations for the management of type 2 diabetes
Vidéo
Clinical recommendations for the management of type 2 diabetes
Afficher le contenu
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
INFOGRAPHIC
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Afficher le contenu
Afficher toutes les ressources Métabolique
Oncology
PLUS RÉCENT

Oncologie

Clinical recommendations for the management of type 2 diabetes
Vidéo
Clinical recommendations for the management of type 2 diabetes
Afficher le contenu
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
INFOGRAPHIC
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Afficher le contenu
Chronic kidney disease management
Vidéo
Chronic kidney disease management
Afficher le contenu
Renal protection with SGLT2 inhibitors: what every cardiologist should know
INFOGRAPHIC
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Afficher le contenu
Afficher toutes les ressources Oncologie
Rare Disease
PLUS RÉCENT

Maladies rares

Optimizing HF discharge care and follow-up
INFOGRAPHIC
Optimizing HF discharge care and follow-up
Afficher le contenu
Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
Vidéo
Managing Type 2 Diabetes Beyond Glycemia : Cardiorenal risk in T2D
Afficher le contenu
Clinical recommendations for the management of type 2 diabetes
Vidéo
Clinical recommendations for the management of type 2 diabetes
Afficher le contenu
Chronic kidney disease management
Vidéo
Chronic kidney disease management
Afficher le contenu
Afficher toutes les ressources Maladies rares
Renal
PLUS RÉCENT

Rénal

Chronic kidney disease management
Vidéo
Chronic kidney disease management
Afficher le contenu
Renal protection with SGLT2 inhibitors: what every cardiologist should know
INFOGRAPHIC
Renal protection with SGLT2 inhibitors: what every cardiologist should know
Afficher le contenu
Kidney outcomes associated with inhibition of SGLT2
Vidéo
Kidney outcomes associated with inhibition of SGLT2
Afficher le contenu
Medicines in chronic kidney disease
INFOGRAPHIC
Medicines in chronic kidney disease
Afficher le contenu
Afficher toutes les ressources Rénal
Respiratory and Immunology
PLUS RÉCENT

Respiratoire et immunologie

What did the study tell us about the safety of medicines in heart failure?
INFOGRAPHIC
What did the study tell us about the safety of medicines in heart failure?
Afficher le contenu
Optimizing HF discharge care and follow-up
INFOGRAPHIC
Optimizing HF discharge care and follow-up
Afficher le contenu
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
INFOGRAPHIC
The benefits of SGLT2 inhibitors in type-2 diabetes, chronic kidney disease and heart failure
Afficher le contenu
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
INFOGRAPHIC
Managing type 2 diabetes beyond glycemia: cardiorenal risk in T2D
Afficher le contenu
Afficher toutes les ressources Respiratoire et immunologie
En vedette
PLUS RÉCENT

Contenu tendance

The story of heart failure prevention with SGLT2 inhibitors in diabetes: Key learnings for cardiologist
PRÉSENTATION
The story of heart failure prevention with SGLT2 inhibitors in diabetes: Key learnings for cardiologist
Afficher le contenu
Cardiologist Practical Guide to Prescribing
INFOGRAPHIC
Cardiologist Practical Guide to Prescribing
Afficher le contenu
Safety and tolerability of SGLT2 inhibitors – how and when should I initiate treatment
Vidéo
Safety and tolerability of SGLT2 inhibitors – how and when should I initiate treatment
Afficher le contenu
Cardiorenal benefits of SGLT2 inhibitors
PRÉSENTATION
Cardiorenal benefits of SGLT2 inhibitors
Afficher le contenu
Diagnosis and co-morbidities of chronic kidney disease
Vidéo
Diagnosis and co-morbidities of chronic kidney disease
Afficher le contenu